Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Returning 1762 results

Notice of Special Interest (NOSI): Availability of Administrative Supplements for Research on Pathobiological Mechanisms of Post-Acute Sequelae of SARS-CoV-2 Infection

Notice of Special Interest
Tuesday, December 7, 2021
Tuesday, January 25, 2022
333
NOT-OD-22-038

Funding Opportunity Purpose

To further the goals of the National Institutes of Health (NIH) Researching COVID to Enhance Recovery (RECOVER) Initiative, the agency encourages applications for [administrative] supplements to current active NIH grants that address the urgent need to identify the pathobiological mechanisms that lead to the multiple symptoms that develop and/or persist long past the time that patients have recovered from the initial stages of the Coronavirus Disease 2019 (COVID-19). Often referred to as Long COVID, these symptoms, which can include fatigue, shortness of breath, brain fog, sleep disorders, fevers, gastrointestinal symptoms, anxiety, and depression, can persist for months and can range from mild to incapacitating. In some cases, new symptoms arise well after the time of infection or evolve over time (e.g., MIS-C). While still being defined, these effects can be collectively referred to as Post-Acute Sequelae of SARS-CoV-2 infection (PASC). Investigators with expertise and insights germane to COVID-19 and PASC pathobiology are strongly encouraged to apply.

Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem

Notice of Special Interest
Friday, December 3, 2021
Wednesday, January 19, 2022
333
NOT-OD-22-033

Funding Opportunity Purpose

The goal of this Notice of Special Interest (NOSI) is to provide support through administrative supplements to strengthen data sharing and data readiness efforts within the HEAL Initiative that further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. This NOSI focuses on data discoverability, and provides an opportunity for existing HEAL Initiative awardees to increase data FAIR-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets. This NOSI is soliciting administrative supplements only from existing awards funded or supplemented by the HEAL Initiative. Applications from HEAL research teams that are already working with data coordinating centers as requirement of the award must provide justification for applying and will be given lower priority. Centers are not eligible to apply. Sharing HEAL-generated results and associated data as rapidly as possible will allow the broader community to ask and answer new research questions; conduct secondary analyses; and address fast-evolving challenges that surround pain management, opioid use and misuse, and overdose.

Limited Competition: Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Clinical Coordinating Center (CCC) (U24 Clinical Trial Not Allowed)

RFA
Friday, November 19, 2021
Wednesday, January 19, 2022
U24
RFA-NS-22-014

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications for the Clinical Coordinating Center (CCC) of Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The CCC will facilitate implementation of clinical trials and will promote high quality and efficient timeliness in trial execution through such methods as master trial agreements and a central Institutional Review Board. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.

Limited Competition: Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Data Coordinating Center (DCC) (U24 Clinical Trial Not Allowed)

RFA
Friday, November 19, 2021
Wednesday, January 19, 2022
U24
RFA-NS-22-013

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications for the Data Coordinating Center (DCC) for Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). The DCC will have responsibility for data management, data quality, statistical analysis, Data Safety Monitoring Board(s) (DSMB) and reporting to regulatory and oversight groups. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.

Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network Clinical Center (Hub) (U24 Clinical Trial Not Allowed)

RFA
Friday, November 19, 2021
Wednesday, January 19, 2022
U24
RFA-NS-22-015

Funding Opportunity Purpose

(Reissue of RFA-NS-16-016) The purpose of this funding opportunity announcement (FOA) is to invite applications from new and existing sites to serve as Clinical Centers (Hubs) in the SIREN Network. SIREN conduct of several multi-center Phase III clinical trials, to improve the outcomes for patients with neurologic, cardiac, respiratory, hematologic, and traumatic conditions. SIREN is made up of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and 11 clinical centers (Hubs). A Hub is usually an academic center or tertiary referral center which actively enrolls patients into all of the clinical trial performed in SIREN. Hubs also provide scientific leadership and administrative oversight to their multiple satellite sites ("Spokes"). Together the Hub and Spokes provide access to a large and varying patient population for clinical trials. SIREN performs a number of simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials are meritorious, peerreviewed projects which are awarded under separate funding announcements.

NIH Blueprint for Neuroscience Research Short Courses in Neurotherapeutics Development (R25 Clinical Trial Not Allowed)

RFA
Friday, October 15, 2021
Friday, December 10, 2021
R25
RFA-NS-21-025

Funding Opportunity Purpose

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint for Neuroscience Research R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA solicits Research Education Grant (R25) applications to develop and implement short courses on neurotherapeutics development for academic neuroscientists. The short courses should provide participants with a sufficient overview of the neurotherapeutics development process to (1) understand the steps required for therapeutics development, (2) anticipate and overcome common challenges in the process, and (3) interact effectively with collaborators who have expertise in various aspects of therapeutics development. The short courses should primarily target independent academic neuroscience researchers and senior post-doctoral fellows interested in incorporating treatment development into their research programs.

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)

RFA
Friday, October 8, 2021
Friday, December 10, 2021
R61/R33
RFA-NS-22-002

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to accelerate development, testing and implementation of evidence-based interventionsthat are culturally and linguistically appropriate for NIH-designated health disparity populations[1] (HDPs)to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes. Applications are encouraged for studies that utilize evidence-based strategies that mitigate: 1) the effects of bias, stigma and discrimination at multiple levels, and 2) socioeconomic, environmental and other barriers to quality pain assessment, treatment and management are desired outcomes of this initiative. Strategies to increase successful HDP patient engagement and bolster inclusion to enhance better pain management outcomes are also desired.

Neurosurgeon Research Career Development Program (NRCDP) (K12 Independent Clinical Trial Not Allowed)

RFA
Monday, October 4, 2021
Thursday, December 16, 2021
K12
RFA-NS-21-019

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications to continue support of a national program of mentored research career development for junior neurosurgeon faculty at institutions nationwide that support neurosurgical research. The goal of the program is to expand the cadre of neurosurgeon investigators trained to conduct research into neurological disorders, making use of their neurosurgical training.

Notice of Change to Key Dates for PAR-22-029 "Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)"

NOT
Tuesday, September 14, 2021
Saturday, October 23, 2021
NOT-NS-22-026

Funding Opportunity Purpose

The purpose of this notice is to extend the due date for PAR-22-029 "Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)".

Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)

RFA
Friday, September 10, 2021
Saturday, November 13, 2021
U24
RFA-NS-22-017

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to have an open competition to support a Coordinating Center for the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium was established under RFA-NS-16-019 and RFA-NS-16-020. The goal of the next phase, under this FOA (Coordinating Center) and RFA-NS-20-005 (sites), is to complete clinical validation of biomarkers initially developed during the first 5-year funding cycle of this program. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data. The Coordinating Center will provide infrastructure and expertise to drive the consortium administratively and contribute scientifically to validation of biomarkers with specified context of use for future clinical trials, including in large phase III trials, with general and diverse populations, and for generating scientific breakthroughs in our understanding and treatment of VCID.

Pages